Treatment of Cutaneous T-cell Lymphoma with a New Aromatic Retinoid (Ro 10-9359)
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
A 77-year-old woman developed a diffuse nodular eruption with histologic, ultrastructural, and biologic evidence of cutaneous T-cell lymphoma (CTCL) limited to the skin. She was treated with a new aromatic retinoid Ro 10-9359 (1 mg/kg/day). After 34 days, the lesions flattened completely and the mononuclear cell infiltrate decreased significantly. No clinical recurrences occurred after a 4-month survey. Discontinuation of the aromatic retinoid led to a relapse with identical clinical and histologic features.
References
1.
Elias P, Williams M
. Retinoids, cancer, and the skin. Arch Dermatol. 1981; 117(3):160-8.
View
2.
Lassus A
. Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro 10-9359). Br J Dermatol. 1980; 102(2):195-202.
DOI: 10.1111/j.1365-2133.1980.tb05692.x.
View
3.
Schnitzler L, Schubert B, Verret J
. [Evaluation of oral retinoid preventive action on human cutaneous epitheliomas (author's transl)]. Ann Dermatol Venereol. 1980; 107(7):657-63.
View
4.
FREDRIKSSON T
. Oral treatment of psoriasis and pustulosis palmo-plantaris with Ro 10-9359. Dermatologica. 1978; 157 Suppl 1:13-8.
DOI: 10.1159/000250879.
View
5.
VAN SCOTT E, Kalmanson J
. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance. Cancer. 1973; 32(1):18-30.
DOI: 10.1002/1097-0142(197307)32:1<18::aid-cncr2820320103>3.0.co;2-q.
View